Capillary Leak Syndrome with Low Serum Albumin During ELZONRIS Treatment
Capillary leak syndrome is a recognised complication during ELZONRIS treatment, triggered by a measurable decline in serum albumin. Prompt identification and correction are central to safe management during the treatment cycle.
This protocol applies when, during ELZONRIS treatment, a patient has a serum albumin below 3.5 g/dL, or when serum albumin has fallen by 0.5 g/dL or more from the value measured before the start of dosing in the current cycle.
The protocol centres on intravenous albumin repletion, administered at specified intervals until the albumin target is reached. The complete administration schedule, defined thresholds, and step-by-step clinical guidance are available in the full structured regimen.
Restore serum albumin to ≥ 3.5 g/dL and ensure it is not reduced by ≥ 0.5 g/dL from the value measured prior to the current cycle's dosing initiation.
References
Serum albumin < 3.5 g/dL or reduced by ≥ 0.5 g/dL from the albumin value measured prior to ELZONRIS dosing initiation of the current cycle
Administer 25 g intravenous albumin every 12 hours (or more frequently as practical) until serum albumin is ≥ 3.5 g/dL AND not reduced by ≥ 0.5 g/dL from the value measured prior to dosing initiation of the current cycle
View source ↗